FY2018 EPS Estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Raised by Analyst (AVDL)

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) – Equities researchers at SunTrust Banks boosted their FY2018 EPS estimates for shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a research note issued to investors on Monday. SunTrust Banks analyst J. Boris now forecasts that the company will post earnings of ($0.97) per share for the year, up from their prior forecast of ($1.01). SunTrust Banks also issued estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s FY2019 earnings at $0.11 EPS, FY2020 earnings at $0.99 EPS and FY2021 earnings at $1.95 EPS.

Other equities analysts also recently issued research reports about the company. BidaskClub raised Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Roth Capital set a $14.00 price target on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, Zacks Investment Research raised Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating and two have issued a buy rating to the company. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share presently has a consensus rating of “Hold” and a consensus target price of $21.50.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ AVDL) traded down $1.30 during trading on Thursday, reaching $7.69. The company’s stock had a trading volume of 4,342,200 shares, compared to its average volume of 377,460. The company has a market cap of $360.36, a P/E ratio of 16.65 and a beta of 1.31. The company has a quick ratio of 1.47, a current ratio of 1.53 and a debt-to-equity ratio of 0.01. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 12 month low of $7.52 and a 12 month high of $12.30.

Institutional investors have recently added to or reduced their stakes in the business. Stifel Financial Corp raised its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 4.3% in the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock valued at $667,000 after buying an additional 2,500 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter valued at about $2,100,000. Virtu KCG Holdings LLC acquired a new position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter valued at about $259,000. Stonepine Capital Management LLC increased its holdings in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 31.7% in the third quarter. Stonepine Capital Management LLC now owns 985,210 shares of the company’s stock valued at $10,345,000 after purchasing an additional 237,347 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter valued at about $733,000. Institutional investors own 64.92% of the company’s stock.

In other Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share news, Director Craig R. Stapleton sold 254,265 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $9.35, for a total value of $2,377,377.75. Following the completion of the sale, the director now directly owns 253,413 shares in the company, valued at $2,369,411.55. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael S. Anderson purchased 5,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was acquired at an average price of $8.86 per share, with a total value of $44,300.00. The disclosure for this purchase can be found here. Corporate insiders own 5.07% of the company’s stock.

WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/15/fy2018-eps-estimates-for-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-raised-by-analyst-avdl.html.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply